PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Clinical features of treatment-naive patients with hepatitis B virus infection: A community-based survey from high- and intermediate-hepatitis B endemicity regions in Southeast China.

Abstract The aim of study was to investigate the clinical features of treatment-naive patients in 2 regions with high- and intermediate-hepatitis B endemicity level in Southeast China and provide the baseline data for monitoring health or planning therapy.This study included 8207 cases of treatment-naive patients with hepatitis B virus (HBV) infection from Yuhuan (YH, high-hepatitis B endemicity region) and Shaoxing (SX, intermediate-hepatitis B endemicity region) during 2014-2015. Clinical data were collected from the patients. Blood samples were kept for detecting hepatitis B surface antigen, hepatitis B envelope antigen (HBeAg), hepatitis B envelope antibody, hepatitis B surface antibody, hepatitis B core antibody, liver function, HBV deoxyribonucleic acid, and alpha-fetoprotein. All persons underwent B ultrasound to exclude liver cirrhosis or cancer.Of all 8207 HBsAg-positive patients, 52.9% patients were in the low-replication (LR) stage and 30.3% in the HBeAg-negative chronic hepatitis B (ENH) stage; 8.8% cases were in the ENH stage with elevated alanine aminotransferase (ALT). More male than female patients were in immune clearance (IC) or ENH stages with elevated ALT (10.4% vs 4.8%, 12.1% vs 5.3%, respectively, P < .05). The percentage of patients in IC and immune tolerant (IT) stages declined with increasing age, whereas the percentages of ENH with elevated ALT stage were highest in 40 to 60 years.The percentage of patients in IT and IC stages was higher in YH than in SX (9.4% vs 3.8%, 9.9% vs 4.2%, respectively, P < .05). More patients had HBVDNA≥10 IU/mL in YH than in SX (24.6% vs 16.0%, P < .05), and more male than female patients had HBVDNA≥10 IU/mL(24.5% vs 17.9%, P < .05).Clinical features varied in treatment-naive patients with HBV infection between different genders and regions. More attention should be paid to the surveillance and therapy of patients in YH especially male patients for the prevention and prognosis of hepatitis B.
PMID
Related Publications

Analysis of hepatitis B virus intrahepatic covalently closed circular DNA and serum viral markers in treatment-naive patients with acute and chronic HBV infection.

Prevalence of hepatitis B in the southeast of China: a population-based study with a large sample size.

Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.

HBsAg, HBeAg and HBV DNA level changes and precore/basal core promoter mutations in the natural history of chronic hepatitis B in Indonesian patients.

Prevalence of hepatitis B in insular regions of southeast China: a community-based study.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 28422873
OWN - NLM
STAT- In-Process
DA  - 20170419
LR  - 20170419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 16
DP  - 2017 Apr
TI  - Clinical features of treatment-naive patients with hepatitis B virus infection: A
      community-based survey from high- and intermediate-hepatitis B endemicity regions
      in Southeast China.
PG  - e6660
LID - 10.1097/MD.0000000000006660 [doi]
AB  - The aim of study was to investigate the clinical features of treatment-naive
      patients in 2 regions with high- and intermediate-hepatitis B endemicity level in
      Southeast China and provide the baseline data for monitoring health or planning
      therapy.This study included 8207 cases of treatment-naive patients with hepatitis
      B virus (HBV) infection from Yuhuan (YH, high-hepatitis B endemicity region) and 
      Shaoxing (SX, intermediate-hepatitis B endemicity region) during 2014-2015.
      Clinical data were collected from the patients. Blood samples were kept for
      detecting hepatitis B surface antigen, hepatitis B envelope antigen (HBeAg),
      hepatitis B envelope antibody, hepatitis B surface antibody, hepatitis B core
      antibody, liver function, HBV deoxyribonucleic acid, and alpha-fetoprotein. All
      persons underwent B ultrasound to exclude liver cirrhosis or cancer.Of all 8207
      HBsAg-positive patients, 52.9% patients were in the low-replication (LR) stage
      and 30.3% in the HBeAg-negative chronic hepatitis B (ENH) stage; 8.8% cases were 
      in the ENH stage with elevated alanine aminotransferase (ALT). More male than
      female patients were in immune clearance (IC) or ENH stages with elevated ALT
      (10.4% vs 4.8%, 12.1% vs 5.3%, respectively, P &lt; .05). The percentage of patients
      in IC and immune tolerant (IT) stages declined with increasing age, whereas the
      percentages of ENH with elevated ALT stage were highest in 40 to 60 years.The
      percentage of patients in IT and IC stages was higher in YH than in SX (9.4% vs
      3.8%, 9.9% vs 4.2%, respectively, P &lt; .05). More patients had HBVDNA&gt;/=10 IU/mL
      in YH than in SX (24.6% vs 16.0%, P &lt; .05), and more male than female patients
      had HBVDNA&gt;/=10 IU/mL(24.5% vs 17.9%, P &lt; .05).Clinical features varied in
      treatment-naive patients with HBV infection between different genders and
      regions. More attention should be paid to the surveillance and therapy of
      patients in YH especially male patients for the prevention and prognosis of
      hepatitis B.
FAU - Wu, Wei
AU  - Wu W
AD  - aState Key Laboratory for Diagnosis and Treatment of Infectious Disease, The
      First Affiliated Hospital, School of Medicine, Zhejiang University bCollaborative
      Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou,
      Zhejiang, People's Republic of China.
FAU - Zhu, Yu
AU  - Zhu Y
FAU - Yu, Chenbo
AU  - Yu C
FAU - Yang, Shigui
AU  - Yang S
FAU - Ruan, Bing
AU  - Ruan B
FAU - Chen, Yu
AU  - Chen Y
FAU - Li, Lanjuan
AU  - Li L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
EDAT- 2017/04/20 06:00
MHDA- 2017/04/20 06:00
CRDT- 2017/04/20 06:00
AID - 10.1097/MD.0000000000006660 [doi]
AID - 00005792-201704210-00054 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Apr;96(16):e6660. doi: 10.1097/MD.0000000000006660.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>